Journal of Hematology & Oncology

Papers
(The H4-Index of Journal of Hematology & Oncology is 94. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-05-01 to 2024-05-01.)
ArticleCitations
Ferroptosis, necroptosis, and pyroptosis in anticancer immunity692
Targeting the Wnt/β-catenin signaling pathway in cancer651
Nanomaterials for cancer therapy: current progress and perspectives500
SARS-CoV-2 binds platelet ACE2 to enhance thrombosis in COVID-19483
EZH2: a novel target for cancer treatment456
Tumor-derived exosomal miR-934 induces macrophage M2 polarization to promote liver metastasis of colorectal cancer373
NK cell-based cancer immunotherapy: from basic biology to clinical development321
Next generation of immune checkpoint inhibitors and beyond304
Regulation of PD-L1 expression in the tumor microenvironment292
Roles of METTL3 in cancer: mechanisms and therapeutic targeting277
cGAS-STING, an important pathway in cancer immunotherapy260
Challenges and advances in clinical applications of mesenchymal stromal cells256
Cancer vaccines as promising immuno-therapeutics: platforms and current progress240
RNA sequencing: new technologies and applications in cancer research237
Tyrosine kinase inhibitors for solid tumors in the past 20 years (2001–2020)233
The MAPK and AMPK signalings: interplay and implication in targeted cancer therapy231
Isolation and characterization of exosomes for cancer research217
Combination strategies to maximize the benefits of cancer immunotherapy216
Dendritic cell biology and its role in tumor immunotherapy210
Proteolysis-targeting chimera (PROTAC) for targeted protein degradation and cancer therapy207
Targeting mutant p53 for cancer therapy: direct and indirect strategies206
Immunosenescence: a key player in cancer development206
Novel therapies emerging in oncology to target the TGF-β pathway203
Targeting hypoxic tumor microenvironment in pancreatic cancer199
Neutrophils in cancer carcinogenesis and metastasis198
Emerging role of exosomes in cancer progression and tumor microenvironment remodeling194
The molecular mechanisms and therapeutic strategies of EMT in tumor progression and metastasis194
Recent advances in CAR-T cell engineering192
Applications of single-cell sequencing in cancer research: progress and perspectives187
Identification of a small molecule as inducer of ferroptosis and apoptosis through ubiquitination of GPX4 in triple negative breast cancer cells186
Liquid biopsy: current technology and clinical applications183
Spatial architecture of the immune microenvironment orchestrates tumor immunity and therapeutic response181
Recent advances in therapeutic strategies for triple-negative breast cancer179
COVID-19 infection in adult patients with hematological malignancies: a European Hematology Association Survey (EPICOVIDEHA)179
Pluripotent stem cell-derived CAR-macrophage cells with antigen-dependent anti-cancer cell functions178
Indoleamine 2,3-dioxygenase 1 (IDO1) inhibitors in clinical trials for cancer immunotherapy169
Targeting cell death pathways for cancer therapy: recent developments in necroptosis, pyroptosis, ferroptosis, and cuproptosis research169
Oncolytic viruses for cancer immunotherapy165
Molecular alterations and targeted therapy in pancreatic ductal adenocarcinoma163
Emerging therapeutic agents for advanced non-small cell lung cancer161
RNA-binding proteins in tumor progression157
Targeting CD47 for cancer immunotherapy155
Impact of hematologic malignancy and type of cancer therapy on COVID-19 severity and mortality: lessons from a large population-based registry study155
Improvement of the anticancer efficacy of PD-1/PD-L1 blockade via combination therapy and PD-L1 regulation151
Burden of anemia and its underlying causes in 204 countries and territories, 1990–2019: results from the Global Burden of Disease Study 2019146
Targeting MCL-1 in cancer: current status and perspectives146
HMGB1 released from GSDME-mediated pyroptotic epithelial cells participates in the tumorigenesis of colitis-associated colorectal cancer through the ERK1/2 pathway144
Fifth-week immunogenicity and safety of anti-SARS-CoV-2 BNT162b2 vaccine in patients with multiple myeloma and myeloproliferative malignancies on active treatment: preliminary data from a single insti143
Chimeric antigen receptor natural killer (CAR-NK) cell design and engineering for cancer therapy142
MEK inhibitors for the treatment of non-small cell lung cancer139
Therapeutic roles of mesenchymal stem cell-derived extracellular vesicles in cancer138
Immunosuppressive cells in cancer: mechanisms and potential therapeutic targets137
Targeting extracellular matrix stiffness and mechanotransducers to improve cancer therapy133
Gut microbiota influence immunotherapy responses: mechanisms and therapeutic strategies132
Antibody–drug conjugates in solid tumors: a look into novel targets131
A WEE1 family business: regulation of mitosis, cancer progression, and therapeutic target131
The consensus from The Chinese Society of Hematology on indications, conditioning regimens and donor selection for allogeneic hematopoietic stem cell transplantation: 2021 update131
Targeted therapy in advanced non-small cell lung cancer: current advances and future trends130
HMGB1 in inflammation and cancer128
Global, regional, and national cancer incidence and death for 29 cancer groups in 2019 and trends analysis of the global cancer burden, 1990–2019128
Cancer stem cell secretome in the tumor microenvironment: a key point for an effective personalized cancer treatment127
Cancer history is an independent risk factor for mortality in hospitalized COVID-19 patients: a propensity score-matched analysis127
Hypoxia-inducible factors: master regulators of hypoxic tumor immune escape123
Modeling neoplastic disease with spheroids and organoids122
The construction, expression, and enhanced anti-tumor activity of YM101: a bispecific antibody simultaneously targeting TGF-β and PD-L1122
VISTA: an immune regulatory protein checking tumor and immune cells in cancer immunotherapy122
XPO1-dependent nuclear export as a target for cancer therapy116
Chimeric antigen receptor-engineered natural killer cells for cancer immunotherapy116
Bispecific T cell engagers: an emerging therapy for management of hematologic malignancies115
IL-7 and CCL19-secreting CAR-T cell therapy for tumors with positive glypican-3 or mesothelin115
Exploring immunotherapy in colorectal cancer114
The global burden and attributable risk factor analysis of acute myeloid leukemia in 195 countries and territories from 1990 to 2017: estimates based on the global burden of disease study 2017112
Emerging agents that target signaling pathways in cancer stem cells110
Role of lysosomes in physiological activities, diseases, and therapy110
Targeting autophagy to overcome drug resistance: further developments110
Insulin-like growth factor receptor signaling in tumorigenesis and drug resistance: a challenge for cancer therapy108
How to select IgG subclasses in developing anti-tumor therapeutic antibodies107
Mesenchymal stem/stromal cells in cancer therapy107
N6-methyladenosine methyltransferases: functions, regulation, and clinical potential107
The management of metastatic GIST: current standard and investigational therapeutics107
tRNA-derived RNA fragments in cancer: current status and future perspectives106
Enhancing the therapeutic efficacy of nanoparticles for cancer treatment using versatile targeted strategies106
BCMA-targeted immunotherapy for multiple myeloma105
High mobility group box 1 (HMGB1): a pivotal regulator of hematopoietic malignancies104
The impact of the temporary suspension of national cancer screening programmes due to the COVID-19 epidemic on the diagnosis of breast and colorectal cancer in the Netherlands103
Emerging agents and regimens for AML103
Evolving therapy of adult acute lymphoblastic leukemia: state-of-the-art treatment and future directions98
The potential role of N7-methylguanosine (m7G) in cancer98
Targeting Akt in cancer for precision therapy98
Advances in synthetic lethality for cancer therapy: cellular mechanism and clinical translation97
Emerging strategies to target RAS signaling in human cancer therapy96
A tertiary center experience of multiple myeloma patients with COVID-19: lessons learned and the path forward95
Immune checkpoint modulators in cancer immunotherapy: recent advances and emerging concepts94
Gene modification strategies for next-generation CAR T cells against solid cancers94
0.03449010848999